Base metrics
- Operating margin
- 34.4%
- Interest coverage
- 1.5x
- Return on equity (ROE)
- 9.3%
Maze Therapeutics, Inc. Common Stock financial statements
메이즈 테라퓨틱스NASDAQ:MAZE · Nasdaq$26.25-0.68%
2026-10-07 closeMaze Therapeutics, Inc. Common Stock's published financial data is dated 2026-10-07. The display ticker is MAZE. The trading market is Nasdaq.
Reported results
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 6.43
Distress
Grey
Safe
- Altman Z''
- 6.43
- Beneish M-Score
- —
- Sloan accrual
- -23.94%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
3/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score3/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Operating margin −5pp
Interest coverage riskInterest coverageBase 1.5x adverse case 1.3x
Return on equity (ROE)Base 9.3% adverse case 5.1%
Revenue −15%
Interest coverage riskInterest coverageBase 1.5x adverse case 1.2x
Return on equity (ROE)Base 9.3% adverse case 4.9%
Interest rate +2pp
Interest coverage riskInterest coverageBase 1.5x adverse case 1.4x
Return on equity (ROE)Base 9.3% adverse case 8.9%
Interest coverage limit
Current margin 11ppInterest coverage limit at an operating margin of 23.4%
Interest expense coverage threshold
Quantus Signal · live data · not investment advice · Privacy Policy